The use of heterologous promoters for adeno-associated virus (AAV) protein expression in AAV vector production

被引:15
|
作者
Ogasawara, Y
Urabe, M
Ozawa, K
机构
[1] Jichi Med Sch, Inst Hematol, Dept Mol Biol, Minami Kawachi, Tochigi 3290431, Japan
[2] Jikei Univ, Sch Med, Dept Internal Med 2, Tokyo 1050003, Japan
关键词
AAV vector; helper plasmid; heterologous promoter; gene therapy;
D O I
10.1111/j.1348-0421.1998.tb02269.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Although adeno-associated virus (AAV) vectors are potentially useful gene transfer vehicles for gene therapy, the vector production system is currently at the developmental stage. We constructed AAV helper plasmids (Rep and Cap expression plasmids) by replacing a native AAV promoter, p5, with various heterologous promoters to examine whether the efficiency of AAV vector production was influenced by modulating the AAV protein expression pattern. The helper plasmids containing heterologous promoters (EF, CMV, SV40, B19p6, and CAG promoters, respectively) expressed Rep78/68 more efficiently than a conventional helper plasmid (pIM45), but the expression of Rep52/40 and Cap decreased, resulting in a significant reduction in AAV vector production. Furthermore, the efficiency of vector production never fully recovered even if the Cap proteins were supplied by an additional expression plasmid. A large amount of Rep78/68 and/or a reduced level of Rep52/40 may have deleterious effects on AAV vector production. The present findings will aid in the development of a more efficient AAV vector production system.
引用
收藏
页码:177 / 185
页数:9
相关论文
共 50 条
  • [1] Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
    Michael F. Naso
    Brian Tomkowicz
    William L. Perry
    William R. Strohl
    [J]. BioDrugs, 2017, 31 : 317 - 334
  • [2] Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
    Naso, Michael F.
    Tomkowicz, Brian
    Perry, William L., III
    Strohl, William R.
    [J]. BIODRUGS, 2017, 31 (04) : 317 - 334
  • [3] Recombinant Adeno-Associated Virus (AAV) Production in the ExpiSf™ Expression System
    Thompson, Kenneth
    Yovcheva, Maya
    Barnes, Sara
    Bundy, Mark
    Van den Berg, Arjen
    Lucki, Natasha
    Zmuda, Jonathan
    Henry, Chiou
    Irvin, Katy
    [J]. MOLECULAR THERAPY, 2020, 28 (04) : 387 - 387
  • [4] ADENO-ASSOCIATED VIRUS (AAV) - A VECTOR FOR STABLE INTEGRATION AND EXPRESSION OF A FOREIGN GENE
    TRATSCHIN, JD
    SMITH, M
    MILLER, IL
    CARTER, BJ
    [J]. EXPERIENTIA, 1985, 41 (06): : 813 - 813
  • [5] Boosters for adeno-associated virus (AAV) vector (r)evolution
    Szumska, Joanna
    Grimm, Dirk
    [J]. CYTOTHERAPY, 2023, 25 (03) : 254 - 260
  • [6] Integration of adeno-associated virus (AAV) and recombinant AAV vectors
    McCarty, DM
    Young, SM
    Samulski, RJ
    [J]. ANNUAL REVIEW OF GENETICS, 2004, 38 : 819 - 845
  • [7] Molecular design of controllable recombinant adeno-associated virus (AAV) expression systems for enhanced vector production
    Johari, Yusuf B.
    Pohle, Thilo H.
    Whitehead, Jared
    Scarrott, Joseph M.
    Liu, Ping
    Mayer, Ayda
    James, David C.
    [J]. BIOTECHNOLOGY JOURNAL, 2024, 19 (06)
  • [8] Reducing the Risk of Adeno-Associated Virus (AAV) Vector Mobilization with AAV Type 5 Vectors
    Hewitt, F. Curtis
    Li, Chengwen
    Gray, Steven J.
    Cockrell, Shelley
    Washburn, Michael
    Samulski, R. Jude
    [J]. JOURNAL OF VIROLOGY, 2009, 83 (08) : 3919 - 3929
  • [9] Genotyping of AAV Plasmid Stocks: Quality Control in Adeno-Associated Virus Vector Production
    Schmitt, Markus
    Pawlita, Michael
    Kleinschmidt, Juergen
    [J]. JOURNAL OF MOLECULAR MICROBIOLOGY AND BIOTECHNOLOGY, 2010, 19 (04) : 204 - 212
  • [10] Production of transgenic bovine embryos by adeno-associated virus (AAV)
    Iqbal, K.
    Kues, W. A.
    Schuhmann, N.
    Buening, H.
    Niemann, H.
    [J]. REPRODUCTION IN DOMESTIC ANIMALS, 2007, 42 : 100 - 101